Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.
An oral insulin by Oramed is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
Oramed will be presenting in the Healthcare Supply Chain forum, 15.00 Taipei time, Tuesday 23 November, through the Healthcare+ B2B.
